Jazz Pharma beats by $0.61, beats on revs; guides FY19 EPS above consensus, revs above consensus
- Reports Q4 (Dec) earnings of $3.64 per share, excluding non-recurring items, $0.61 better than the S&P Capital IQ Consensus of $3.03; revenues rose 9.2% year/year to $476.46 mln vs the $459.48 mln S&P Capital IQ Consensus.
- "Our evolution as a global biopharmaceutical company continued in 2018 as we delivered another year of record revenues and made substantial progress on key milestones, including advancing multiple pre-clinical, early- and late-stage development programs. We also initiated a broad development program to generate data for Vyxeos in new AML patient populations and other hematologic malignancies," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "In 2019, our strong financial position and scalable operations provide a foundation for further growth as we focus on key regulatory approvals, planned product launches, our development pipeline and multiple initiatives to maximize our commercial portfolio."
- Co issues upside guidance for FY19, sees EPS of $14.30-15.00, excluding non-recurring items, vs. $13.98 S&P Capital IQ Consensus; sees FY19 revs of $2.05-2.13 bln vs. $2.03 bln S&P Capital IQ Consensus.